TransCode Therapeutics Implements 1-for-28 Reverse Stock Split to Maintain Nasdaq Compliance

TransCode Therapeutics, a clinical-stage RNA oncology company, will implement a 1-for-28 reverse stock split effective May 15, 2025, at 12:01 a.m. EDT. The strategic financial maneuver aims to raise the company's per-share price and maintain compliance with Nasdaq's minimum bid price requirement.

Under the approved split, the company's outstanding common stock will decrease from approximately 23.3 million to about 833,620 shares. No fractional shares will be issued, with amounts rounded up to the nearest whole share. Vstock Transfer LLC will serve as the exchange agent, and the new stock will continue trading under the existing ticker 'RNAZ'.

The reverse stock split represents a common strategy for companies seeking to avoid delisting from major stock exchanges by increasing their share price. For TransCode, which focuses on developing RNA therapeutics to treat metastatic cancer, this move signals a proactive approach to maintaining financial market standing while continuing to advance its innovative cancer treatment research.

Investors should note that while the total number of shares will decrease, the overall market capitalization of the company remains unchanged. The split is designed to potentially improve investor perception and provide more flexibility in future capital raising efforts.